Article

Treating patients with ocular hypertension: preserving sight or a waste of resources?

In a point-counterpoint debate, David L. Epstein, MD, Duke University Medical Center, Durham, NC, advocated treatment for most ocular hypertensive patients, drawing an analogy to treatment of systemic hypertension.

Chicago-In a point-counterpoint debate, David L. Epstein, MD, Duke University Medical Center, Durham, NC, advocated treatment for most ocular hypertensive patients, drawing an analogy to treatment of systemic hypertension. Taking the opposite view, Paul R. Lichter, MD, University of Michigan, Ann Arbor, recommended treating only patients at high risk for ocular hypertension but noting that a key issue is deciding where to draw that line.

“Intraocular pressure is not some vague risk factor, it is a causative factor,” Dr. Epstein said, thus even moderately high IOP levels warrant intervention. In addition, visual field changes that may occur as disease progresses affect quality of life, and declining to treat certain patients violates the “golden rule” of treating others as you would treat your own eyes, he added.

Until methods of early detection improve, “we need to treat more patients rather than less,” he concluded.

Dr. Lichter recommended treating only high-risk patients, arguing that the financial burden, side effects, and inconvenience of medical therapy should not be inflicted on others. Instead, it is better to treat only those whose individual risk factors suggest that they face a high risk of conversion.

“There is not a shred of evidence that treating ocular hypertension is beneficial,” he said.

However, he urged that patients in the Ocular Hypertension Treatment Study continue to be followed so that additional data on their long-term outcome and disease progression can be evaluated to help clarify which patients should be treated and at what point.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.